Dow Jones
38.225,66 +322,37 (+0,85%) Nasdaq
15.840,96 +235,48 (+1,51%) Nikkei 225
38.236,07 -37,98 (-0,10%) EUR/USD
1,0733 +0,0006 (+0,05%) Bitcoin EUR
55.233,82 +1.243,95 (+2,30%) CMC Crypto 200
1.278,93 +8,19 (+0,64%)
Dyne Therapeutics, Inc. (DYN)
Dopo ore:
| Chiusura precedente | 25,83 |
| Aperto | 26,34 |
| Denaro | 25,92 x 100 |
| Lettera | 25,99 x 100 |
| Min-Max giorno | 24,79 - 27,11 |
| Intervallo di 52 settimane | 6,40 - 30,27 |
| Volume | |
| Media Volume | 1.267.998 |
| Capitalizzazione | 2,241B |
| Beta (5 anni mensile) | 0,95 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -3,95 |
| Prossima data utili | 09 mag 2024 - 13 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 37,75 |
GlobeNewswireDyne Therapeutics to Present at October Investor Conferences
WALTHAM, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to present at the following investor conferences in October: Chardan’s 7th Annual Genetic Medicines Conference, fireside chat on Tuesday, October 3, 2023 at 11:00 a.m. ET in New York Jefferies Inaugural Biotech
- GlobeNewswire
Dyne Therapeutics Receives FDA Orphan Drug Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
- On Track to Report Initial Data from the Global, Multiple Ascending Dose Phase 1/2 ACHIEVE Clinical Trial in the Second Half of 2023 - WALTHAM, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for DYNE-101 for
- GlobeNewswire
Dyne Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
WALTHAM, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference being held in New York on Monday, September 11, 2023 at 4:15 p.m. ET. A live webcast will be available in the Inv
